ExGen 500 is an efficient vector for gene delivery to lung epithelial cells in vitro and in vivo
Stefano Ferrari(University of Padua), Maurizio Scarpa(University of Udine), Andrea Pettenazzo(University of Padua), Enrico Moro(University of Padua), Franco Zacchello(University of Padua), J-P Behr(Laboratoire de Chimie)
Cited by 252
Related Papers
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy
|European Journal of Pediatrics|2007|522
Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
|The Journal of Pediatrics|2006|364
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
|Journal of Cerebral Blood Flow & Metabolism|2012|307
Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management
|Journal of Inherited Metabolic Disease|2011|302
Possible strategies to cross the blood–brain barrier
|The Italian Journal of Pediatrics/Italian journal of pediatrics|2018|255